Quick Facts

• Therapeutic Focus: Management of conditions related to excess stomach acid.
• Key Uses: Addressing gastric and duodenal ulcers.
• Reflux Management: Provides care for gastroesophageal reflux disease (GERD).
• Tissue Care: Supports the healing of erosive esophagitis (acid-related damage to the esophagus lining).
• Specialized Condition: Utilized for pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.

---

What ОмеВел treats: main uses and benefits

ОмеВел is indicated for the treatment and management of various conditions associated with high levels of stomach acid. The medication is utilized in the care of active duodenal ulcers and gastric ulcers. It is further used in combination with other agents for the management of ulcers associated with H. pylori bacterial infection to support the reduction of ulcer recurrence.

The drug is an appropriate option for addressing symptoms linked to Gastroesophageal Reflux Disease (GERD). For patients experiencing acid-related damage to the esophageal lining, known as erosive esophagitis, ОмеВел is a component of a therapeutic plan to promote healing and to help maintain that healing. Additionally, the medication is applied for the long-term management of conditions where the stomach produces an excessive amount of acid, including specialized cases like Zollinger-Ellison syndrome.

Regulatory References

1. NIH MedlinePlus guidance

The eligibility profile for ОмеВел (Omeprazole) is defined by strict regulatory-based restrictions, age minimums, and specific patient conditions, as established by governmental authorities.

---

Classification	Population/Condition	Regulatory Status
Contraindicated	Hypersensitivity to omeprazole or substituted benzimidazoles.	Absolute Non-Eligibility
	Concomitant use with the antiviral drug nelfinavir.	Prohibited
Age-Related	Adults for all labeled uses.	Established
	Pediatric patients ge 1 year (for GERD/erosive esophagitis).	Established
	Infants < 1 year for most indications.	Safety/Effectiveness Not Established
Conditional Use	Severe Hepatic Impairment (Liver Disease).	Dose reduction considered
	Lactation/Nursing Mothers.	Not Recommended

---

Use is restricted based on absolute contraindications to the drug class or concurrent use of specific antiretrovirals. Regulatory documents require special consideration for patients with severe liver impairment, where a dose adjustment may be necessary. Furthermore, the official labeling clarifies that the use of Omeprazole is not recommended while breastfeeding and its efficacy has not been formally established in infants younger than one year of age.

Interactions with other medicines and products

ОмеВел (Omeprazole) has officially documented interactions primarily related to its influence on the CYP2C19 enzyme system and its effect of increasing gastric pH.

Contraindicated Combinations

Co-administration with Nelfinavir and Rilpivirine is strictly contraindicated or prohibited in regulatory labeling due to documented reductions in the plasma concentrations of these antiretroviral medicines.

Documented Exposure Modification

As a CYP2C19 inhibitor, Omeprazole reduces the active formation of medicines like Clopidogrel, which requires caution. It also prolongs the elimination of Warfarin and Phenytoin, necessitating clinical monitoring. By increasing gastric pH, Omeprazole significantly reduces the absorption and exposure of drugs that require an acidic environment, such as Atazanavir and certain antifungals, while paradoxically increasing the exposure of others, including Digoxin.

Other Significant Interactions

Regulatory documentation advises against co-administration with strong enzyme inducers like St. John's Wort and Rifampin, as they may significantly reduce Omeprazole concentrations. Additionally, Omeprazole may elevate the systemic exposure of Methotrexate and its metabolite. For diagnostic purposes, Omeprazole increases the serum level of Chromogranin A (CgA), requiring the drug to be stopped for at least 14 days prior to CgA testing.

The mechanism of action for ОмеВел (Omeprazole) is rooted in its highly selective and persistent inhibition of the stomach's primary acid-producing enzyme.

Irreversible Blockade of the Gastric Proton Pump

ОмеВел acts as a specific irreversible inhibitor of the H^+/ K^+-ATPase enzyme, commonly known as the proton pump, which is located in the parietal cells. This enzymatic blockade prevents the exchange of hydrogen ions ( H^+) for potassium ions ( K^+), which is the final step in hydrochloric acid ( HCl) secretion. This action leads to a significant and sustained decrease in gastric acidity. The irreversible nature of the inhibition means the effect persists until the stomach synthesizes new H^+/ K^+-ATPase enzyme molecules.

Targeted Acid-Dependent Bioactivation

ОмеВел is a prodrug that is chemically activated selectively by the highly acidic environment of the parietal cell canaliculi. This conversion targets the active drug directly to the enzyme site, concentrating the inhibitory effect. This targeted activation effectively modulates the chemical environment of the upper gastrointestinal tract by suppressing the final stage of the acid secretory pathway.

How to Use ОмеВел (Omeprazole): Administration Guidelines

Omeprazole is administered via oral and intravenous (IV) routes. The medication is available primarily as delayed-release capsules or tablets and as a powder for injection.

Most conditions require once daily (OD) dosing, typically 20 mg or 40 mg. However, regimens for H. pylori eradication require 20 mg twice daily (BID) as part of combination therapy. Daily doses exceeding 80 mg for pathological hypersecretory conditions (PHC) must be administered in divided doses.

---

Essential Administration Instructions

Usage Instruction	Requirement
Timing	Should be taken before eating, ideally prior to the first meal of the day.
Intake Method	Delayed-release capsules/tablets must be swallowed whole and not chewed or crushed to preserve the enteric coating.
Alternative Intake	The capsule contents (pellets) may be mixed with a small amount of soft, slightly acidic food, like applesauce, or juice for immediate swallowing if the patient cannot swallow whole capsules.
Course Duration	Ranges from short-term (4 to 8 weeks for active ulcers) to long-term (for maintenance of healed erosive esophagitis or chronic PHC).

---

Special Population Dosing Rules

Dosage adjustments are necessary only for specific groups. Dosing for pediatric patients is determined by body weight. For adults with severe hepatic impairment, a lower maximum daily dose, often limited to 20 mg, is recommended. No adjustment is typically required for patients with renal impairment or for the elderly.

These administration guidelines establish the standardized protocol for the use of Omeprazole, focusing on the required logistical execution of the therapeutic regimen.

Research Evidence / Overview of Studies for ОмеВел

---

Evidence for Healing and Maintenance of Ulcers and Erosions

Research has been conducted on ОмеВел using Randomized Controlled Trials (RCTs) and meta-analyses to examine the measured changes in patients with peptic ulcers and acid-related damage, focusing on epithelial integrity and recurrence.

For duodenal ulcers and gastric ulcers, studies monitored how these conditions evolved over short time intervals. Research examined outcomes related to physical discomfort and the actual repair of the ulcer, as confirmed by endoscopy. Findings describe patterns observed where measurements of ulcer healing were reported. Other research explored outcomes related to the recurrence of ulcers linked to H. pylori infection when ОмеВел was used in combination with antibiotics. For erosive esophagitis, studies monitored measurements of mucosal integrity over short-term treatment periods, with further research exploring the long-term use for continuous acid management in people whose erosions have achieved epithelial integrity.

---

Evidence for Symptom Management and Reflux Disease

For symptoms related to Gastroesophageal Reflux Disease (GERD), research examined patient-reported experiences and symptom patterns. This evidence is derived mainly from short-term RCTs and includes various subjective measurement tools. Data show patterns related to symptom evolution in the patient populations studied, and this research contributes to the broader evidence landscape concerning short-term or episodic symptom patterns.

---

Research Gaps and What Remains Uncertain

While the evidence base for ОмеВел is substantial, certain aspects remain uncertain. The long-term effects are not fully established beyond the typical trial periods. Comparative evidence is lacking for direct head-to-head comparisons against some of the newest medications now available. Data for certain groups remain insufficient, and subgroup findings are uncertain regarding the long-term patterns for some patients. Research does not determine whether an individual will respond similarly; findings describe group patterns, and results apply only to the specific populations studied.

Key Studies & References

1. Randomized Controlled Trial: Omeprazole versus ranitidine in the treatment of reflux esophagitis

Common questions about ОмеВел (FAQ)

Q: What is ОмеВел used for?

ОмеВел is a prescription medication often used in the management of certain conditions related to excessive stomach acid production. Clinical studies support its use for short-term treatment of active duodenal ulcer and active benign gastric ulcer. It may also be used for gastroesophageal reflux disease (GERD). Your healthcare provider determines the appropriate use for your specific needs.

Q: How does ОмеВел work in the body?

Research suggests that ОмеВел affects a specific enzyme system in the stomach lining cells. This action leads to a reduction in the secretion of acid into the stomach. The ultimate clinical effect observed is a lowered level of acidity within the stomach, which may assist in the healing of acid-related erosions.

Q: What common side effects were reported in clinical trials?

In research trials, the most commonly reported adverse events were generally mild and included headache, abdominal pain, diarrhea, nausea, and flatulence. Not everyone experiences side effects, and individuals should discuss any concerns with a healthcare professional.

Q: Is ОмеВел a fast-acting drug?

Available evidence indicates that relief of symptoms may occur within the first few days of starting treatment. However, the time required for complete healing, such as of an ulcer, can vary among individuals and often requires adherence to the full prescribed course of therapy.

Q: Can ОмеВел be taken with other medications?

ОмеВел has the potential to interact with many other prescription and non-prescription products. It is important to provide your healthcare professional with a complete list of all medications, vitamins, and supplements you are currently taking, as they will evaluate potential interactions.

Omeprazole must be stored according to specific regulatory conditions to maintain stability. The medicine requires storage at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F), with a strict mandate to protect from moisture and light. It must be kept in the container it came in, with the lid tightly closed. Certain packaging is required to be stored in the original package to ensure moisture protection.

Regulatory labeling requires that Omeprazole be kept out of the sight and reach of children and safety caps must always be locked. If the capsule is mixed with food for administration, the mixture must be swallowed immediately and cannot be stored.

For disposal, outdated or unused medicine should be discarded. Patients must consult a healthcare professional or pharmacist for proper disposal methods, as all pharmaceutical waste must be handled in accordance with local requirements.